March 17, 2025 – Ostial Corp., a privately held medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, has acquired the Wavella technology from Crossfire Medical. The company also unveiled its new identity as Verge Medical, marking a strategic expansion in the coronary and peripheral markets, with product offerings now in the inpatient and office-based settings.
Wavella is a specialty infusion catheter designed to improve procedural efficiency and patient comfort in venous applications. The patented technology employs a rotating sinusoidal wire that will simultaneously deliver physician-specified agents, ensuring comprehensive, segmental agent delivery in the peripheral vasculature.
"We are excited to launch Verge Medical as the next chapter in our company’s evolution," said Mike Buck, CEO of Verge Medical. "This acquisition expands our growing portfolio, reshaping the future of vascular interventions by enhancing coronary and peripheral treatments while optimizing procedural efficiency, safety, and patient outcomes. Verge Medical is actively pursuing additional medical device innovations to expand its pipeline and advance its mission."
Verge Medical advances its legacy with the FLASH™ Aorto-Ostial Angioplasty System, the company’s first commercial product, which has been used in over 25,000 procedures to date. The Ostial FLASH System enables 360° lesion coverage for streamlined vessel reaccess and optimized outcomes. With Ostial FLASH and the newly acquired Wavella technology,
Verge Medical is positioned at the forefront of vascular innovation, providing technologies designed to enhance procedural outcomes and elevate patient care.
Wavella is an investigational device and is not yet available for commercial use.
For more information, visit www.vergemedical.com.
March 14, 2025 
